

The Journal of Infectious Diseases

Volume 129 Number 2 February 1974

JIDIAQ 129 93-232 (1974)

Medical Microbiology / Clinical Immunology / Epidemiology

Official publication of the Infectious Diseases Society of America Published by the University of Chicago Press



Dr. Reddy's Laboratories, Ltd., et al.
v.
Galderma Laboratories, Inc.
IPR2015-_____

**DOCKET
ALARM**

Find authenticated court documents without watermarks at docketalarm.com.

The Journal of Infectious Diseases

Official Publication of the Infectious Diseases Society of America

Edward H. Kass, *Editor*
K. Frank Austen, *Associate Editor*
John F. Enders, *Associate Editor*
William R. McCabe, *Associate Editor*
Morton N. Swartz, *Associate Editor*

Louis Weinstein, *Associate Editor*
Mary M. Eichhorn Adams, *Managing Editor*
Amy M. Levin, *Editorial Assistant*
Julie McCoy Spaulding, *Editorial Assistant*
Elizabeth C. Krome, *Editorial Assistant*

EDITORIAL BOARD

Robert Austrian, Philadelphia, Pa.
William R. Barclay, Chicago, Ill.
Robert M. Chanock, Bethesda, Md.
Harold S. Ginsberg, Philadelphia, Pa.
Saul Krugman, New York, N.Y.
Calvin M. Kunin, Madison, Wis.
Alexander D. Langmuir, Boston, Mass.
John C. Sherris, Seattle, Wash.
John P. Utz, Richmond, Va.

INTERNATIONAL BOARD OF EDITORS

Paul B. Beeson, Oxford, England
Louis Chedid, Paris, France
Frank Fenner, Canberra, Australia
W. R. O. Goslings, Leiden, Netherlands
Per Hedlund, Gothenburg, Sweden
Janusz Jeljaszewicz, Warsaw, Poland
Kiyoshi Konno, Sendai, Japan
Guido Majno, Geneva, Switzerland
A. A. Miles, London, England
Ciro A. Peluffo, Montevideo, Uruguay
Albert B. Sabin, Rehovot, Israel

The Infectious Diseases Society of America was founded in 1963 to meet the needs for a forum for scientists interested in laboratory and clinical aspects of infectious diseases, medical microbiology, and immunology. The *Journal of Infectious Diseases*, for many years not affiliated with a specific scientific body, became an editorial responsibility of the Society with the issue of January, 1969. The *Journal* will consider for publication any meritorious investigation or review within the full range of interests of the Society's membership. These encompass pathogenesis, diagnosis, or treatment of diseases due to infectious agents or to disorders of immune mechanisms. The *Journal* is published monthly at the University of Chicago Press, 5801 Ellis Avenue, Chicago, Illinois 60637.

Communications for the editors and manuscripts should be addressed to The Editor, The Journal of Infectious Diseases, Channing Laboratory, Boston City Hospital, Boston, Massachusetts 02118.

Business correspondence should be addressed to The University of Chicago Press, 5801 Ellis Avenue, Chicago, Illinois 60637.

Subscription rates for U.S.A. and possessions: institutions, \$50.00; American Society for Microbiology, \$18.00; other individuals, \$25.00. Canada and Pan American Postal Union; institutions, \$55.00; American Society for Microbiology, \$19.00; other individuals, \$27.50. All other countries: institutions, \$60.00; American Society for Microbiology, \$20.00; other individuals, \$30.00. A special rate of \$15.00 in the U.S.A. (\$16.00 in other countries) is available for students, fellows, interns, and residents; all requests for this rate must be accompanied by a letter of authorization from the subscriber's faculty adviser or department head. (Limit of two years at this rate.) Single copies: institutions, \$5.00; individuals, \$3.50. Advertising rates and information are available from the Journals Advertising Manager, The University of Chicago Press, 5801 Ellis Avenue, Chicago, Illinois 60637. Advertising is accepted subject to approval by editorial committee; acceptance does not imply endorsement by the *Journal*. Forms close the first of the month, two months preceding date of issue.

Claims for missing numbers should be made within the month following the regular month of publication. The publishers expect to supply missing numbers free only when losses have been sustained in transit and when the reserve stock will permit.

Second-class postage paid at the Post Office at Chicago, Illinois, and an additional mailing office. Notice to Subscribers: If you change your address, please notify us and your local postmaster immediately. The Post Office does not forward second-class mail.

Cover design by Albert Alcalay.

Published by the University of Chicago Press, Chicago, Illinois 60637; The University of Chicago Press, London, S. W. 1.

© 1974 by the University of Chicago. All rights reserved.

ISSN0022-1899

Effects of Tetracycline on Leukotaxis

R. Russell Martin, Glenn A. Warr, Robert B. Couch,
Henry Yeager, and Vernon Knight

From the Departments of Medicine and of
Microbiology and Immunology,
Baylor College of Medicine, Houston, Texas

Tetracycline, in concentrations common during therapy, markedly depressed migration of human leukocytes in vitro. Sera from 12 of 13 volunteers who received oral tetracycline after infection with *Mycoplasma pneumoniae* inhibited leukotaxis of normal leukocytes. Random migration and chemotaxis of leukocytes from two additional subjects were depressed for up to 24 hr after a single 1-g dose of tetracycline. When tetracycline was tested over a wide range of concentrations, leukotaxis was depressed by lower concentrations (0.01–10 µg/ml) but was stimulated by higher concentrations (30–300 µg/ml) of the antibiotic. Metabolic studies revealed that production of leukocyte lactate was elevated significantly in the presence of a high level of tetracycline. The mechanisms by which tetracycline affects leukotaxis are not known.

Leukotaxis (the migration of leukocytes toward an attracting stimulus) is one of the fundamental responses of polymorphonuclear leukocytes. This property has been examined in vitro with various modifications of the micropore filter chamber developed by Boyden [1]. Numerous substances have been shown to attract leukocytes, including bacterial culture filtrates [2, 3], extracts from leukocytes themselves [4], components of the serum complement system [5, 6], and tissues infected with virus [7, 8].

The effects on polymorphonuclear leukocytes of drugs used in treatment of infections are usually monitored by the observation of changes in counts of total and differential leukocytes in the peripheral blood. The possibility that therapy with drugs may alter some of the functions of peripheral blood leukocytes has not been extensively investigated. However, Ward [9] and Peters et al. [10] have described the effects of corticosteroids on leukotaxis in vitro and in vivo, respectively.

Received for publication March 5, 1973, and in revised form August 20, 1973.

This investigation was supported by grants from the AMA-ERF Committee for Research on Tobacco and Health, by the National Tuberculosis and Respiratory Diseases Association, by contract no. NAS 9-13139 P/1 from the National Aeronautics and Space Administration, and by grants no. RR-00350, PH 43-NIAID-68-963, and 1 T01 AI00446-01 from the U.S. Public Health Service.

Please address requests for reprints to Dr. R. Russell Martin, Department of Medicine, Baylor College of Medicine, 1200 Moursund Avenue, Houston, Texas 77025.

We became interested in the effects of tetracycline on leukotaxis when we observed reduced migration of leukocytes in a group of volunteers receiving this antibiotic [11]. The present studies extend these observations by means of a systematic evaluation of the influence of tetracycline on leukotaxis, measured in vitro.

Materials and Methods

Experimental infection with *Mycoplasma pneumoniae* was produced in normal volunteers by intranasal and nasopharyngeal inoculation of 2 ml of broth containing 1×10^6 cfu of *M. pneumoniae*. These volunteers had initial low ($\leq 1:2$) or negative titers of growth-inhibiting antibody to *M. pneumoniae* in serum, and all volunteers became infected, as evidenced by a fourfold rise in antibody titer in serum and by repeated isolation of *M. pneumoniae* from throat swab specimens.

Leukocytes were collected after sedimentation of anticoagulated blood in dextran, as previously described [12]. A portion of the separately collected serum was used on the day obtained, and the rest was stored at -70°C for subsequent tests.

The system used for leukotaxis has been described in detail [11]. Briefly, the modified Boyden chambers used were similar to those described by Cornely [4] and consisted of two compartments, separated by a 13-mm diameter Millipore® filter (SSWP 01300) with a mean pore size of 3 µm. The upper chamber held a volume of 0.35 ml containing 1.3×10^6 leukocytes, and the lower

chamber contained a total volume of 1.0 ml. To test migration of leukocytes toward an antigen, 1.3×10^6 leukocytes in 0.35 ml of fluid were added to the upper chamber, and 0.1 ml of antigen was placed in the lower chamber. For tests with mycoplasma antigen and influenza vaccine, the basic medium was Hanks' balanced salt solution with 1% gelatin (Hanks'-gel). The influenza antigen used was zonally purified, dialyzed monovalent influenza vaccine (A₂/Hong Kong/Aichi/68, Eli Lilly, Indianapolis, Ind.) with a potency of 1,600 chick cell-agglutinating units/ml. In tests with serum, a final concentration in serum of 10% was used in both upper and lower chambers.

Preliminary studies of the time-course of migration of leukocytes in the chambers revealed that leukocytes counted on the lower surface of the filters increased linearly between 60 and 90 min, then reached a plateau until 240 min, after which a decrease was noted. Incubations were conducted for 2 hr, with temperature maintained at 37 C by circulating water at a constant temperature. Filters were processed for microscopy, and for each filter, leukocytes on the bottom surface were counted in 10 random microscopic fields at a magnification of $\times 400$ [11]. Leukotaxis was expressed as the number of leukocytes migrating completely through to the bottom surface of the filter. Thus, for each condition of incubation for each subject, counts were made of a total of 30 random microscopic fields. Under the conditions described, virtually all of the cells counted were polymorphonuclear leukocytes.

In incubations with tetracycline, tetracycline HCl (USP, kindly supplied by the Upjohn Co., Kalamazoo, Mich.) was used in final concentrations of 0.01–300 $\mu\text{g}/\text{ml}$. Each of the two volunteers received an oral 1.0-g dose of tetracycline (TETREX[®] *bid*CAPS[®], Bristol Laboratories, Syracuse, N.Y.). The volunteers with infection due to mycoplasma received 250 mg of tetracycline four times daily on days 22–28 after inoculation. Levels of tetracycline in serum were measured by the agar diffusion method of Bennett et al. [13].

Metabolic studies of leukocytes. Determinations were made on three separate occasions with leukocytes from the same individual. Leukocytes were placed in Hanks'-gel solution with 10% autologous serum and 0.050 ml of D-glucose-U-14C (specific activity 0.022–0.064 Ci/mole, New

England Nuclear, Boston, Mass.). Triplicate incubations were performed in 25-ml flasks with plastic wells (Kontes Glass, Vineland, N.J.) under three experimental conditions: with no added antibiotic, with 1 μg of tetracycline phosphate/ml, and with 300 μg of tetracycline phosphate/ml. Additional controls included flasks without leukocytes and flasks containing acid-treated leukocytes. The mixtures were kept at 4 C in the interval between the addition of radioisotope and the beginning of incubation. The flasks were gassed for 10 min with 95% O₂–5% CO₂, then incubated for 2 hr at 37 C at 68 oscillations/min in a Dubnoff metabolic shaker. After incubation, 1.0 ml was withdrawn for determination of glucose. Hydroxide of hyamine, 0.4 ml (Packard Instrument Co., Downers Grove, Ill.), was added to the plastic wells to trap ¹⁴CO₂, which was measured by pipetting 0.100 ml of hyamine solution into 15 ml of toluene containing 1.0 mg of 2,5 diphenzloxazole/ml and 0.25 mg of 1,4-bis-2-(5-phenyloxazolyl)-benzene/ml. Samples were counted in a Packard Tri-Carb model 3375 liquid scintillation counter and were corrected for quenching by the standard external technique.

The glucose remaining after incubation was determined by measurement of glucose enzymatically (Sigma Chemical, St. Louis, Mo.) in flasks with and without cells; production of lactic acid was measured enzymatically (Sigma Chemical) as the difference between content of lactic acid in supernatant fluid of flasks with tissue that had been incubated and that in those that had been initially killed with acid.

Results

The inhibitory effects of tetracycline on migration of leukocytes were discovered during a serial study of leukotaxis in which white blood cells and sera from 13 adult volunteers with experimental *M. pneumoniae* infection were used [11]. In the final week of that study, on days 22–28 after infection, 13 volunteers received 1.0 g of tetracycline each day in an attempt to reduce carriage of *M. pneumoniae*. The random migration of leukocytes incubated in autologous serum obtained on day 29 (one day after completion of therapy with oral tetracycline) was 36% lower (χ^2 , $P < 0.01$) than random migration of the same leukocytes in con-




Figure 1. Random migration (no chemotactic agent in lower chamber) and chemotaxis (mycoplasma antigen in lower chamber) of autologous leukocytes collected from 13 volunteers on day 29 after infection with mycoplasmas. Clear bars show mean \pm SE of migration in serum before infection (day 0), while dark bars show migration in serum taken on day 29.

Although chemotaxis of leukocytes toward mycoplasma was maintained in sera from day 29 (migration was greater with mycoplasma than with no antigen present, χ^2 , $P < 0.01$), migration was lower in magnitude than expected, based on other observations [11]. The possibility that sera from day 29 might interfere with leukotaxis was considered.

The effects of these sera on migration of homologous leukocytes were then studied. Leukocytes from a single normal donor were tested simultaneously with sera obtained from the 13 volunteers at the start of the study (day 0) and at the completion of therapy with tetracycline (day 29). Levels of tetracycline in the sera from day 29 were $\leq 5 \mu\text{g/ml}$. The random migration of leukocytes (no chemotactic agent in the lower compart-

of 33 leukocytes per high-power field in serum from day 0, decreasing to 21 leukocytes per high-power field in serum from day 29 (figure 2). In 12 of the 13 individual serum pairs, migration of the homologous leukocytes was lower in serum from day 29 than in serum from day 0 from the same volunteer (paired t -test, $P < 0.01$). That this was not a result of the handling and storage of the sera was demonstrated by the unchanged values for migration of leukocytes in the serum from a normal control subject who did not receive tetracycline, but whose serum was collected and similarly processed.

There was a similar suppressive effect by sera from day 29 on chemotaxis toward mycoplasma antigen of homologous leukocytes from the same donor (figure 3). In 10 of the 13 serum pairs, chemotaxis was reduced in serum from day 29 compared with migration in serum from day 0 (paired t -test, $P < 0.05$). In one instance migration of leukocytes was the same in both sera, while chemotaxis of leukocytes was higher in sera from day 29 in two instances. Leukotaxis was reduced




Figure 2. Random migration of homologous leukocytes from a normal donor in sera collected before illness (day 0) and on day 29 after infection with mycoplasmas. Migration in individual serum pairs is represented by \bullet — \bullet . Migration in a normal control serum is represented by \circ — \circ . Brackets show

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.